Vixtra inc. proposes to offer health care providers on a global scale innovative products based on unique combinations of compounds delivered by patented slow-release technologies that when used together provide distinct advantages in clinical outcomes, ease of use as well as cost savings when compared to existing therapeutic interventions.
A team of globally recognized physicians, researchers & pharmaceutical industry leaders have assembled to form Vixtra. This company will develop, manufacture and distribute globally novel combination pharmaceutical products using in-licensed proven patented slow release and other technologies.
Vixtra inc. is currently in its first round of funding with a business model offering an impressive ROI using an accelerated time to market model while offering low risk to success.